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ARTICLE
Artiﬁcial cell membrane binding thrombin
constructs drive in situ ﬁbrin hydrogel formation
Robert C. Deller1,5, Thomas Richardson 1,2, Rebecca Richardson 3, Laura Bevan3, Ioannis Zampetakis4,
Fabrizio Scarpa 4 & Adam W. Perriman1
Cell membrane re-engineering is emerging as a powerful tool for the development of next
generation cell therapies, as it allows the user to augment therapeutic cells to provide
additional functionalities, such as homing, adhesion or hypoxia resistance. To date, however,
there are few examples where the plasma membrane is re-engineered to display active
enzymes that promote extracellular matrix protein assembly. Here, we report on a self-
contained matrix-forming system where the membrane of human mesenchymal stem cells is
modiﬁed to display a novel thrombin construct, giving rise to spontaneous ﬁbrin hydrogel
nucleation and growth at near human plasma concentrations of ﬁbrinogen. The cell mem-
brane modiﬁcation process is realised through the synthesis of a membrane-binding super-
cationic thrombin-polymer surfactant complex. Signiﬁcantly, the resulting robust cellular
ﬁbrin hydrogel constructs can be differentiated down osteogenic and adipogenic lineages,
giving rise to self-supporting monoliths that exhibit Young’s moduli that reﬂect their
respective extracellular matrix compositions.
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As advanced cellular-based therapies approach clinicaltranslation, there is an increasing demand for new cellspeciﬁc matrices that provide improved therapeutic per-
formance1. However, rational matrix design is extremely chal-
lenging, as cell phenotype and fate are reliant on a wide range of
scaffold-dependent environmental factors, which include cell
adhesion, chemical composition, cell receptor stimulation, micro-
and nanomorphology, and mechanical stiffness2,3. These factors
come into play almost immediately, as in vitro tissue engineering
typically begins with the seeding and adhesion of cells onto a
biocompatible and biodegradable scaffold, which acts as a sur-
rogate for the extracellular matrix (ECM)4. As the cells proliferate
and/or differentiate, they produce ECM that gradually replaces
the scaffold material, giving rise to a structurally self-supporting
entity5.
A range of biocompatible natural polymers have been used to
produce transient hydrogel scaffolds for tissue engineering,
including chitosan, gelatin, collagen, hyaluronic acid and ﬁbrin6.
Of these biopolymer-based scaffolds, ﬁbrin hydrogels are
amongst the most popular, as they can be readily produced in situ
at room temperature via proteolytic cleavage7. Fibrin formation
in vivo occurs as a response to injury, culminating with the
proteolytic cleavage of prothrombin to thrombin, which is a
serine protease that catalyses the polymerization of ﬁbrinogen to
ﬁbrin, resulting in the formation of a ﬁbrin hydrogel clot8.
Importantly, ﬁbrin hydrogels display speciﬁc peptide motifs, such
as RGD, which promote adhesion via integrin signalling, and
mediate the recruitment, activation and presentation of growth
factors (e.g. BMP-2 and TGF-β1), which help regulate osteogenic
and chondrogenic differentiation in human mesenchymal stem
cells (hMSCs)9–11. Moreover, a key advantage of (ﬁbrin) hydro-
gels over solid porous scaffolds such as poly(lactide-co-glycolide)
is their ability to be delivered via injection12, although extrusion-
based shear stress can result in a reduction in cell viability13.
Cell membrane engineering is emerging as a premier approach
for cell augmentation, as it can be used to rapidly provide addi-
tional cell functionality, including immunoevasion, adhesion and
homing14. However, there are few examples where cell membrane
modiﬁcations have been used to drive in situ scaffold formation.
Wu et al.15 and Cruise et al.16 irradiated cells coated in the
photosensitive dyes eosin and polyethylene (glycol) diacrylate to
generate hydrogel structures on the surface of lung adenocarci-
noma cells and porcine islets, respectively, although both systems
required synthetic monomers and an external source of radiation.
Here, we describe a methodology involving the synthesis of
supercationic thrombin-polymer surfactant complexes that
spontaneously bind the plasma membrane of hMSCs and drive
in situ ﬁbrin hydrogel nucleation and growth (Fig. 1). The
resulting self-supporting hydrogel constructs support high levels
of metabolic activity, and provide a matrix for adipogenic and
osteogenic differentiation. Moreover, we demonstrate that this
cell functionalisation methodology is facile and can be used to
inject thrombin labelled GFP-expressing ﬁbroblasts into an
in vivo zebraﬁsh skin wound model.
Results
Artiﬁcial membrane binding thrombin synthesis. The synthesis
of the cell membrane binding thrombin (bovine) complex was
performed using a two-step process (Fig. 2a). The initial step
involved the kinetically controlled cationization of thrombin via
N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride
(EDC) mediated covalent attachment of cationic N,N′-dimethyl-
1,3-propanediamine (DMPA) to surface exposed carboxylic acid
functional groups to generate an active supercationic thrombin
(sc_thrombin) construct (Supplementary Fig. 1)17. Thrombin not
only contains glutamic acid (21) and aspartic acid (18) residues,
but also acid functional groups arising from posttranslational
modiﬁcations, including up to 10 ɣ-carboxyglutamyl residues that
each contain two carboxylic acid groups18 and carboxylic acid
groups resulting from the N-linked glycosylation of three aspar-
agine residues19. Accordingly, the reaction conditions were
carefully controlled (pH, temperature, and the number of EDC
and DMPA equivalents) and the enzyme cationization reaction
progress was monitored using zeta potentiometry, which shifted
from −13.9 ± 0.9 to +5.8 ± 0.3 mV over a 2 h period (Fig. 2b). As
the active site of thrombin contains the serine protease catalytic
triad including a reactive aspartic acid (Asp189)20, it was neces-
sary to concomitantly evaluate the activity of the thrombin during
the reaction. This was achieved by monitoring the increase in
ﬁbrinogen solution turbidity resulting from ﬁbrin gel formation,
which showed a steady decrease in reaction rate as the cationi-
zation reaction progressed over the 2 h period (Fig. 2c). To bal-
ance the effective cationic surface charge density required for
electrostatic surfactant conjugation with high enough levels of
enzymatic activity, the reaction was quenched at 60 min and these
conditions used for all subsequent experiments. Matrix assisted
laser desorption ionisation time of ﬂight mass spectroscopy per-
formed on the resulting sc_thrombin (Fig. 2d), showed an average
increase in mass of 3.25 kDa, which signiﬁed charge reversal
(negative to positive) at 39 sites.
While it has been shown that supercationic proteins such as
supercharged green ﬂuorescent protein have a high membrane
binding afﬁnity, strong electrostatic interactions with the anionic
sulfonated proteoglycans of the glycocalyx results in rapid
endocytosis21,22. This transient behaviour has been used to good
effect for the delivery of siRNA23, as has the cationic polymer
poly(ethylenimine) (PEI) for nucleic acid24 and protein25
delivery. However, our principle objective was to display the
active thrombin at the cell surface in order to nucleate a ﬁbrin gel
from the plasma membrane. Therefore, a second step involved
electrostatically conjugating the anionic polymer surfactant
glycolic acid ethoxylate 4-nonylphenyl ether (ox890), which
comprises an anionic carboxylic acid headgroup, a hydrophilic
poly(ethylene)glycol central moiety (E40) and a hydrophobic
nonylphenyl tail (Supplementary Fig. 2 & Supplementary
Methods). Signiﬁcantly, we have recently shown that this
approach can be used to generate a polymer surfactant corona
on the surface of myoglobin that reconﬁgures to insert into the
plasma membrane of hMSCs17. Here, electrostatic conjugation of
the polymer surfactant (≈120 molecules per protein) to the
Fig. 1 Schematic showing in situ ﬁbrin hydrogel formation from the
membranes of bone-marrow derived human mesenchymal stem cells
(hMSCs). Artiﬁcial membrane binding thrombin constructs comprising
supercationic thrombin molecules (white) surrounded by a polymer
surfactant corona (yellow) that associates with surface exposed cationic
(red) residues spontaneously insert into bilayer regions of hMSC plasma
membranes. In the presence of ﬁbrinogen, the membrane-immobilised
thrombin catalyses ﬁbrin formation (blue ﬁbres) within the interstitial
spaces between the cells giving rise to a self-supporting hydrogel monolith
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sc_thrombin to yield [sc_thrombin][ox890] resulted in an
negative shift in the zeta potential distribution (Supplementary
Fig. 3). Dynamic light scattering experiments (Supplementary
Fig. 4) performed on solutions of thrombin, sc_thrombin and
[sc_thrombin][ox890], gave particle size number distributions
centred at approximately 5 nm, with a small increase in
hydrodynamic diameter distribution after surfactant conjugation,
which is consistent with previous reports17,26–28.
Surfactant conjugation did not result in a reduction in catalytic
activity (cf. sc_thrombin) (Supplementary Fig. 5), and confocal
ﬂuorescence microscopy from ﬁbrinogen solutions supplemented
with Alexa Fluor® 594 dye-labelled ﬁbrinogen showed the
presence of a complex ﬁbrin network after treatment with either
thrombin, sc_thrombin or [sc_thrombin][ox890] (Supplementary
Fig. 6 & Supplementary Methods). Moreover, unconﬁned
compression testing of the resulting self-supporting structures
gave Young’s moduli (Supplementary Fig. 7) that were consistent
with soft ﬁbrin hydrogels29.
Thrombin construct membrane afﬁnity and hydrogel forma-
tion. A clinical application for thrombin functionalised cells
could be readily derived from in vitro tissue engineered con-
structs that utilise transient ﬁbrin scaffolds. Accordingly, bone
marrow derived hMSCs with well-characterised differentiation
pathways (e.g. adipogenic, chondrogenic and osteogenic) were
selected to assess membrane adhesion and cell metabolic activ-
ity30. Initially, a monolayer of hMSCs was incubated with 1 μM
Rhodamine B labelled analogues (rh_thrombin, rh_sc_thrombin
and [rh_sc_thrombin][ox890]) for 20 min and subsequently
washed to remove any unbound protein. Signiﬁcantly, this
resulted in increases in Rhodamine B ﬂuorescence from hMSCs
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Fig. 2 The synthesis and characterisation of the supercationic thrombin-polymer surfactant conjugate. a Schematic showing the electrostatic surface
potential of native and supercationic thrombin (sc_thrombin) (PDB; 1UVS) at pH 7, highlighting the anionic (blue) and cationic (red) charged regions.
Generation of the polymer surfactant corona (green halo) via electrostatic coupling of glycolic acid ethoxylate 4-nonylphenyl ether (ox890) to sc_thrombin
gives [sc_thrombin][ox890]. b Zeta potential (ca. pH7; n= 3) of thrombin as a function of cationization times (0–120min). Data reported as means ±
standard deviation (s.d.). c Rate of ﬁbrinogen solution (3.125mgmL−1) gelation as measured by changes in turbidity (600 nm) catalysed by sc_thrombin
subjected to various cationization times (0–120min). Data shown as one-phase association curves of raw data. d MALDI-TOF MS spectra (m/z= 3) of
native and sc_thrombin (60min). Source data are provided as a Source Data ﬁle
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labelled with either rh_sc_thrombin or [rh_sc_thrombin][ox890],
signifying insertion and retention to the plasma membrane of the
hMSCs. Thereafter, hMSCs were labelled with a plasma mem-
brane speciﬁc dye (CellMask™ DeepRed) and imaged immediately
(Fig. 3a–c & Supplementary Fig. 8), which showed colocalisation
with the rh_sc_thrombin or [rh_sc_thrombin][ox890] constructs,
which conﬁrmed plasma membrane binding. Furthermore, the
presence of the rh_sc_thrombin and [rh_sc_thrombin][ox890]
construct could be detected over a period of at least 6 h (Sup-
plementary Movie 1), although a signiﬁcant proportion of both
rh_sc_thrombin and [rh_sc_thrombin][ox890] was endocytosed
during this period. To test in situ ﬁbrin formation from the
[rh_sc_thrombin][ox890] functionalised cells over time, a 10 mg
mL−1 ﬁbrinogen solution supplemented with Alexa Fluor® 488
dye-labelled ﬁbrinogen was added to a conﬂuent layer of the
hMSCs. Here, time-lapse confocal ﬂuorescence microscopy shows
nucleation and growth from the cells in both the x–y plane and z
direction (Supplementary Movie 2 & Supplementary Fig. 9).
MTS assays31 were performed to measure the relative
metabolic activity of hMSCs labelled with the [sc_thrombin]
[ox890], which showed no signiﬁcant reduction up to concentra-
tions as high as 2.6 μM (p= 0.087) (Fig. 3d). Accordingly, a 1 μM
[sc_thrombin][ox890] incubation concentration was selected for
all subsequent experiments, as this afforded suitable catalytic
activity, membrane loading potential and biocompatibility, and
was within the physiological concentration range of (pro)
thrombin in plasma32. Moreover, control cell metabolic activity
assays were also performed using the neat oxidised surfactant
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Fig. 3 Evaluation of rh_thrombin, rh_sc_thrombin and [rh_sc_thrombin][ox890] hMSC plasma membrane afﬁnity. Cells labelled with CellMask™ Deep Red
(green) and corresponding rhodamine labelled thrombin (magenta). a Native (rh_thrombin) thrombin at T= 0 h. b Cationised (sc_rh_thrombin) thrombin
at T= 0 h. c Polymer surfactant conjugate ([rh_sc_thrombin][ox890]) thrombin at T= 0 h. Scale bars represent 50 µm. d MTS cell metabolic activity
assay (n= 8) of hMSCs after labelling with [sc_thrombin][ox890] compared to unlabelled controls. Data reported as means ± s.d. Dunnett’s test; *p≤
0.05, **p≤ 0.001. Source data are provided as a Source Data ﬁle
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(ox890) and its synthetic precursor (Supplementary Fig. 10 &
Supplementary Methods), which showed no signiﬁcant cytotoxi-
city up to the highest concentrations tested (25 mM).
In order to further assay the enzymatic activity of the hMSC
membrane-bound [sc_thrombin][ox890] construct, a low (1 mg
mL−1) ﬁbrinogen solution supplemented with Alexa Fluor® 594
dye labelled ﬁbrinogen was introduced in complete medium
without FBS (to prevent FBS-driven ﬁbrin formation). Signiﬁ-
cantly, confocal ﬂuorescence microscopy images show ﬁbrin
structures emanating from the plasma membrane of the hMSC
monolayer (Fig. 4a & Supplementary Movie 3) after 20 min, along
with limited ﬁbrin networks in acellular regions, indicating gel
nucleation from tissue culture treated plastic bound [sc_throm-
bin][ox890]. This is in contrast to hMSCs devoid of [sc_throm-
bin][ox890] labelling and in the absence of FBS where no ﬁbrin
formation was observed after 60 min (Supplementary Fig. 11).
The membrane labelling protocol was then modiﬁed to generate
3D ﬁbrin hydrogel constructs containing 1 × 107 cell mL−1
(Dia.= 6.5 mm; Vol.= 100 μL; ≈1 × 106 cells) (Fig. 4b). Here,
conﬂuent hMSCs were labelled with 1 μM [sc_thrombin][ox890],
re-suspended in FBS-free culture media supplemented with 6 mg
mL−1 ﬁbrinogen, and pipetted into wells coated in a 1 wt.%
agarose gel. Fibrin gelation was allowed to proceed for a period of
60 min prior to the addition of an equal volume of high glucose
media supplemented with 20% (v/v) FBS and 0.1 TIUmL−1
aprotinin to limit ﬁbrin degradation33. After 24 h, the constructs
were ﬁxed and imaged using scanning electron microscopy
(Fig. 4c), which showed dense cellular aggregates with individual
cells surrounded by a 3D ﬁbrin matrix. Z-stacks produced using
live cell confocal ﬂuorescence microscopy showed a well-
dispersed distribution of hMSCs, uniformly suspended within
the ﬁbrin hydrogel matrix (Supplementary Movie 4 & Supple-
mentary Fig. 12).
hMSC differentiation and mechanical properties. In order to
investigate the ability of the ﬁbrin hydrogel system to sustain 3D
cultures for the extended periods of time required for tissue
engineering, the metabolic activity of hMSCs within the ﬁbrin
constructs was monitored over 22 days using a MTS cell meta-
bolic assay. Cells were cultured in a medium that maintained
hMSC multipotency to avoid changes in innate cell metabolic
activity due to differentiation, which allowed the relative increase
in cell number to be estimated. Signiﬁcantly, a constant increase
in the ratio of the formazan product (490 nm) to the MTS
reactant (387 nm) was observed over the entire period, which
indicated sustained levels of hMSC proliferation (Fig. 5a).
Reverse transcription quantitative polymerase chain reaction
(RT-qPCR) experiments were performed to monitor the early-
stages of differentiation of the [sc_thrombin][ox890] modiﬁed
hMSCs in the ﬁbrin hydrogel system. The PPAR-γ gene is a
pivotal ligand-activated transcription factor that upon activation
is upregulated and drives hMSCs towards an adipogenic fate34.
Accordingly, upregulated PPAR-γ expression was used as an early
indicator of adipogenic differentiation (14 days), which showed a
7-fold increase when the hMSCs were cultured in adipogenic
media (cf. standard media) (Fig. 5b). To probe the capability of
cells to undergo chondrogenesis, the relative expression of the
chondrogenic gene SOX9 was explored35. SOX9 is upregulated in
response to the addition of chondrogenic factors (e.g. TGF-β3)
and downregulated in the presence of osteogenic factors (e.g.
BMP-2), with its expression linked to the activity of the
osteoresponsive gene RUNX236. Here, SOX9 expression in the
ﬁbrin constructs supplemented with chondrogenic media resulted
in a 4-fold increase in SOX9 expression (cf. osteogenic media)
after 7 days (Fig. 5c). However, no signiﬁcant increase in RUNX2
expression was apparent in the ﬁbrin constructs supplemented
with osteogenic media (cf. standard media) after 7 days
(Supplementary Fig. 13).
Following on from the RT-qPCR experiments, the hMSC ﬁbrin
constructs were differentiated down adipogenic or osteogenic
lineages over a 21 day period to enable the potential for
development of typical phenotypic traits30,37. Aside from visual
changes in cell morphology, analysis of the resulting constructs
were probed by the addition of speciﬁc ﬂuorescent stains relevant
for each lineage. This included Oil Red O for lipid vacuole
formation during adipogenesis38 and Alizarin Red for calcium
deposition resulting from osteogenesis39. For the modiﬁed cells
exposed to the adipogenic media, confocal ﬂuorescence micro-
scopy images showed clusters of lipid vacuoles, emanating from
cells with a globular morphology, which was consistent with the
formation of mature adipocytes (Fig. 5d). Conversely, modiﬁed
cells exposed to the osteogenic media exhibited extensive calcium
deposition, signifying osteogenesis, which was accompanied by
a
b
c
Fig. 4 Evaluation of cellular ﬁbrin hydrogel formation. a Live-cell confocal
ﬂuorescence micrograph (2D) showing Alexa Fluor® 594 labelled ﬁbrin
(red) nucleation after 20min from the surface of hMSCs stained with
Calcein AM (green) and Hoechst 33342 (blue). Insert shows single cell at
higher magniﬁcation. Scale bars represent 100 and 10 μm (insert).
b Photographs of the free-standing ﬁbrin hydrogels 24 h after gelation
formed via [sc_thrombin][ox890] hMSCs labelling. c Scanning electron
micrograph of [sc_thrombin][ox890] modiﬁed hMSCs aggregates (3D)
after 24 h showing a surface catalysed ﬁbrin matrix. Insert shows cells at
higher magniﬁcation. Scale bars represent 50 and 5 μm (insert)
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subtle changes away from a spindle-like morphology (but not
cuboidal), highlight the ongoing transition toward the formation
of fully mature osteoblasts (Fig. 5d)40. Both phenotypes were also
observed across a wider population of cells, liberated, re-plated
(overnight) and imaged in 2D (Supplementary Fig. 14).
The differentiation pathways of hMSCs are dependent on the
mechanical properties of their environment, with stiffer interfaces
generally favouring an osteogenic fate and softer surfaces
adipogenesis41–43. In practice, this means that ECM formation
during tissue engineering can provide positive feedback to
differentiation, as it can directly impact on the stiffness of the
surrounding environment. For example, the deposition of
calcium phosphate during osteogenic biomineralization can result
in an increase in stiffness in the surrounding environment, which
in turn can stabilise the osteoblast phenotype44. To explore the
impact of ECM formation on the mechanical properties,
unconﬁned compression testing (Fig. 6a, b) was performed on
the constructs (Dia.= 8.0 mm; Vol.= 400 µL; ≈ 4 × 106 cells)
formed from 6mg mL−1 ﬁbrinogen solutions cultured in either
osteogenic, adipogenic or standard expansion medium for a
period of 23 days. These were compared to constructs cultured
for 1 day (containing hMSCs) in standard expansion media, and
with constructs devoid of hMSCs and catalysed using 200 nM
native thrombin. Signiﬁcant differences between each system
were observed, with day 1 Young’s compressive moduli of 8.1 kPa
in ﬁbrin only constructs, which increased to 12.2 kPa in the
presence of hMSCs. After 23 days, hMSCs undergoing osteogen-
esis exhibited a much higher stiffness (34.2 kPa), when compared
with those undergoing adipogenesis (24.6 kPa) or multipotency
culture conditions (15.4 kPa) (Fig. 6c). These results indicate that
the cell membrane nucleated ﬁbrin structures are amenable to
scaffold-matrix remodelling by the differentiated cells, and that
the resulting ECM inﬂuences the bulk compressive mechanical
properties45.
In vivo localisation of thrombin-modiﬁed ﬁbroblasts. Although
the development of the membrane re-engineering approach
described above could prove advantageous for in vitro tissue
engineering, the ability to produce thrombin coated cells ad hoc
that could be injected into a site of injury provides new oppor-
tunities for in vivo tissue engineering. Here, an injury site would
be preferable as endogenous ﬁbrinogen is freely available within
intravascular ﬂuids such as blood plasma at between 1.5 and
4 mgmL−1 46. However the clinical use of exogenous ﬁbrinogen
within ﬁbrin sealants may also permit administration to other
sites47. Accordingly, we performed preliminary cell transplant
studies using an in vivo zebraﬁsh model system to examine the
isolation, labelling, delivery and survival of a different cell type,
namely, primary zebraﬁsh ﬁbroblasts. Zebraﬁsh (Danio rerio) are
an established model organism and provide an excellent platform
for live cell imaging with numerous cell type speciﬁc ﬂuorophore-
expressing strains available (Supplementary Fig. 15)48. Zebraﬁsh
have also been considered as a model organism for studying
thrombolytic and haemostatic processes49 and furthermore,
haemostatic activity has been observed by the infusion of acti-
vated bovine thrombin to zebraﬁsh in vivo as a method to assess
the availability of clottable ﬁbrinogen in antithrombin III
mutants50. Consequently, ﬁbroblasts from GFP-expressing ET37
ﬁsh51 (Supplementary Fig. 16) were isolated by FACS (Supple-
mentary Fig. 17) prior to immediate labelling with the
[sc_thrombin][ox890] conjugate. Cells were then washed and
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Fig. 5 Cell metabolic activity and differentiation potential of hMSCs within
in situ formed ﬁbrin hydrogel constructs. a MTS cell metabolic activity
assay (n≥ 4) of hMSCs at various intervals after ﬁbrin construct formation.
Data reported as the mean ratio of product:reactant ± s.d. b Relative
expression (n= 8) of PPAR-γ in [sc_thrombin][ox890] coated hMSCs
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One-tailed paired t-test; **p≤ 0.01. c Relative expression (n= 9) of SOX9 in
[sc_thrombin][ox890] coated hMSCs within catalysed ﬁbrin, cultured in
chondrogenic or osteogenic medium for 7 days. Data reported as means ±
s.e.m. One-tailed paired t-test; *p≤ 0.05. d Confocal ﬂuorescence
micrographs (Z-projections) of individual (top) and groups of (bottom)
cells within ﬁbrin constructs with scale bars representing 10 and 50 μm,
respectively. Cells stained with Hoechst 33342 (blue) differentiated down
adipogenic (left) and stained with oil red o (red) and osteogenic (right) and
stained with alizarin red (magenta) lineages. Source data are provided as a
Source Data ﬁle
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re-suspended, with donor labelled (GFP+) ﬁbroblasts (micro)
injected around the site of a fresh ventral incisional injury in
adult, non-transgenic recipient zebraﬁsh (Fig. 7a, b). Signiﬁcantly,
similar numbers of viable unlabelled and thrombin-functionalised
labelled cells were observed at 3 days post (micro)injection (dpi),
suggesting normal cell survival (Fig. 7c, d). Macroscopic obser-
vations and histological analysis of sections through the incisional
injury revealed no adverse effects between ﬁsh injected with
labelled and unlabelled ﬁbroblasts (Fig. 7e, f), however further
investigations will be required to determine precise effects on
speciﬁc wound healing processes.
Herein, we described the synthesis and characterisation of a
new membrane active thrombin construct that can be used to
drive in situ ﬁbrin formation from the plasma membranes of stem
cells. The resulting hydrogel constructs support high levels of
viability and proliferation in hMSCs cultures over 22 days, which
can be readily differentiated to produce self-supporting tissue
engineered constructs. Unconﬁned compression testing showed
that differentiation of the hMSCs down well-deﬁned adipogenic
and osteogenic pathways directly impacted the Young’s moduli of
the resulting structures, which indicates high levels of integration
between the nucleated ﬁbrin hydrogel and the resulting ECM.
The facile membrane labelling strategy and tissue engineering
protocols described above provide a new approach to both
in vitro and in vivo tissue engineering, although a detailed
understanding of the temporal behaviour of the membrane-
bound thrombin constructs (e.g., internalisation and deactivation
of the enzyme) would need to be ascertained before clinical
translation. This is key, as controlling the concentration of
bioavailable thrombin, is a fundamental requirement in the
development of haemostatic products.
Methods
Materials. All materials unless otherwise speciﬁed were purchased from Sigma-
Aldrich Company Ltd (Poole, UK) or ThermoFisher Scientiﬁc Ltd (Loughborough,
UK) and were of the highest available purity.
Human mesenchymal stem cells. Human mesenchymal stem cells (hMSCs)
derived from human bone marrow were sourced with informed consent from
healthy donors from Southmead Hospital, Bristol, UK in full accordance with
Bristol Southmead Hospital Research Ethics Committee guidelines (reference #078/
01), North Bristol NHS Trust.
Cationization, surfactant oxidation and conjugation. For protein cationization a
2 mgmL−1 solution of protein (Bovine Thrombin, Sigma-Aldrich Company Ltd,
Cat. No. T7326 (https://www.uniprot.org/uniprot/P00735)) was dissolved in 60
mM HEPES (pH7). A solution (adjusted to pH 7) of DMPA equivalent to
approximately 150-fold the number of cationizable sites was added along with solid
N-(3-dimethylaminopropyl)-N′ethylcarbodiimide hydrochloride (EDC) equivalent
to ~34-fold the number of cationizable sites, yielding a ﬁnal protein concentration
of 1 mgmL−1. The complete mixture was then adjusted to pH 6.5 and stirred for
60 min (or as indicated) at 25 °C. Afterwards, excess DMPA and EDC were
removed by diluting 4-fold with 20 mM HEPES (pH7) at 4 °C and using 10 K
MWCO spin concentrators. Dilution and spin concentration as aforementioned
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Fig. 6 Compression testing of 3D hMSC ﬁbrin hydrogel constructs. Images
of a 3D hMSC ﬁbrin hydrogel construct (Dia.= 8.0mm; depth ∼4.2 mm;
≈4 × 106 cells) before (a) and during (b) unconﬁned compression testing.
c Compressive modulus (n= 4) of ﬁbrin gels containing [sc_thrombin]
[ox890] coated hMSCs cultured for 23 days in undifferentiated, adipogenic
or osteogenic media, [sc_thrombin][ox890] coated hMSCs cultured for 1
day in undifferentiated media and native thrombin (200 nM) catalysed (no
hMSCs) after 1 day. Data reported as the means ± s.e.m. Tukey’s test; **p≤
0.05 ***p≤ 0.005. Source data are provided as a Source Data ﬁle
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Fig. 7 In vivo zebraﬁsh injury and [sc_thrombin][ox890] labelled GFP+
ﬁbroblast addition. Schematic representation of the in vivo adult zebraﬁsh
injury model. a Wildtype (non-transgenic) recipient zebraﬁsh were
anaesthetized and a 4mm incisional injury made on the ventral upper
thorax. A lateral view is shown. b Unlabelled or [sc_thrombin][ox890]
labelled, FACS sorted GFP+ ﬁbroblasts were injected at six sites around the
edge of the incisional injury. At the desired time-point, ﬁsh were sacriﬁced
and the tissue surrounding the incision was ﬁxed, imaged and embedded
for sectioning. A ventral view is shown. Ventral view of the area of tissue
surrounding the incision at 3 dpi following transfer of c unlabelled or
d [sc_thrombin][ox890] labelled GFP+ ﬁbroblasts. Similar numbers of
cells were retained at all wounds. The red line depicts the approximate
position of the incisional injury which is fully re-epithelialized at this stage.
Sections through the injury region at 3 dpi following transfer of e unlabelled
or f [sc_thrombin][ox890] labelled GFP+ ﬁbroblasts. No obvious
differences were observed between wounds containing labelled or
unlabelled cells. Arrows indicate the position of the incision. All scale bars
represent 250 µm
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was repeated a minimum of ﬁve times to limit further cationization and protein
concentration veriﬁed using a Pierce™ BCA protein assay kit (ThermoFisher Sci-
entiﬁc Ltd, Cat. No. 23225). Samples were then stored at −20 °C prior to further
use for up to 72 h. Surfactant oxidation was achieved by the complete oxidation of
the terminal hydroxyl group of IGEPAL Co890 to yield a terminal carboxylic acid
functional group. Two grams of IGEPAL Co890 dissolved in 50 mL of deionized
water was mixed with 30 mg 2,2,6,6,-tetramethyl-1-piperidinyloxyl (TEMPO), 50
mg sodium bromide and 5 mL of a sodium hypochlorite solution containing 10-15
% available chlorine. The solution was adjusted to pH 11 and then stirred overnight
at room temperature before the reaction was quenched with the addition of 10 mL
of ethanol and adjusted to pH 1 prior to a solvent extraction with three 80 mL
aliquots of chloroform. The combined chloroform fractions were washed with
three 80 mL aliquots of ddH2O at pH 1 and chloroform removed by rotary eva-
poration (40 °C/150 mbar). The resulting product was dissolved in 40 mL of
ethanol at 65 °C and then recrystallized overnight at −20 °C. The following day the
ethanol was decanted with this process repeated once more prior to removing any
residual ethanol by rotary evaporation (50 °C/120 mbar) to yield a fully oxidized
product. Surfactant conjugation was achieved by dissolving the oxidized product
directly into the desired protein solution at room temperature at a concentration
equivalent to 1.4 the total number of glutamic acid, aspartic acid, lysine and
arginine residues and stirred for a period 1 h and protein concentration veriﬁed
using a Pierce™ BCA protein assay kit. Samples were then used immediately or
stored at −20 °C prior to further use for up to 72 h.
Zeta potentiometry. Zeta potentiometry was performed on a Zetasizer Nano ZSP
(Malvern Instruments Ltd, UK) with a minimum of three replicates taken at the
indicated pH values and a temperature of 25 °C. The values reported show the
mean (mV) with error bars representing ± standard deviation (s.d.).
Matrix assisted laser desorption ionisation time of ﬂight mass spectrometry.
Matrix assisted laser desorption ionisation time of ﬂight (MALDI-TOF) mass
spectrometry was performed on a UltraﬂeXtreme mass spectrometer (Bruker (UK)
Ltd, Coventry, UK) using a matrix of containing a saturated solution of α-Cyano-4-
hydroxycinnamic acid in acetonitrile with 0.1% triﬂuoroacetic acid in a 1:1 ratio of
sample in H2O mixed and spotted onto a 384-well plate with a ground steel surface
prior to ionization and detection (100% laser power/+ve ion mode).
rh_thrombin, rh_sc_thrombin and [rh_sc_thrombin][ox890] co-localisation.
Preparations of 1 μM rh_thrombin, rh_sc_thrombin and [rh_sc_thrombin][ox890]
were produced by the addition of a 15-fold molar excess of NHS-rhodamine
(DMSO) to Thrombin (PBS) at 4 °C for 120 min. Excess NHS-rhodamine was
removed using a spin concentrator (MWCO: 10 kDa) with 20 mM HEPES (pH 7)
buffer. Conjugation efﬁciency was then determined using UV-visible spectroscopy
by measuring relative intensities at 280 nm (protein) and 555 nm (rhodamine)52.
Cells were labelled with 1 μM of the desired thrombin solutions in DMEM media
(no FBS) with 60 mM HEPES (pH7) for 20 min prior to washing with PBS.
Thereafter, cells were labelled with CellMask™ DeepRed following the as supplied
instructions prior to imaging in complete medium ((DMEM low (1000mg L−1)
glucose supplemented with 100 μgmL−1 streptomycin, 2mM Glutamax, 100 UmL−1
penicillin, 10% (v/v) FBS, 5 ngmL−1 ﬁbroblast growth factor).
sc_thrombin catalytic activity. Assessment of sc_thrombin (0.05 mgmL−1) cat-
alytic activity subjected to various cationization times (0–120 min) was completed
by measuring changes in turbidity (600 nm) at 25 °C by UV-visible spectroscopy
(Agilent Technologies LDA U.K. Limited, Stockport, U.K.) of a 3.125 mgmL−1
solution of ﬁbrinogen (total volume; 200 μL) with increasing in turbidity indicative
of ﬁbrin formation.
[sc_thrombin][ox890] Cytotoxicity. Sterile (0.22 μm ﬁltered) stock solutions of
[sc_thrombin][ox890] at 10.30 μM (≈0.38 mgmL−1) in 20 mM HEPES pH7 were
prepared and diluted to the appropriate protein concentration with a ﬁnal buffer
concentration of 60 mM HEPES buffer (pH7). To start, complete medium was
aspirated from conﬂuent low passage (<5) hMSCs in a 96 well plate (1 × 104 cells/
well) and cells then rinsed with 100 μL of PBS prior to the addition of 100 μL of the
appropriate solution (0-9.27 μM/eight replicates) to cells and incubated for a period
of 20 min at 37 °C/5% CO2. After 20 min cells were rinsed twice with 100 μL PBS
prior to assessment of cell metabolic activity by the MTS cell metabolic assay. MTS
cell metabolic activity assays were performed using a CellTiter 96® AQueous One
Solution Cell Proliferation Assay kit (Promega UK Ltd, Cat. No. G3582) following
the as supplied instructions with hMSCs incubated for a period of 3 h prior to
analysis by UV-visible spectroscopy at 490 nm with values expressed as a per-
centage in comparison to untreated controls.
Fibrin construct formation. Conﬂuent hMSCs (<4) were cultured in 175 cm2
ﬂasks in complete medium. Up to 32 wells (as desired) within a 96-well plate were
precoated with 50 μL 1 wt.% agarose, with surrounding wells ﬁlled with 200 μL of
water containing 100 μgmL−1 streptomycin, 100UmL−1 penicillin and 250 μgmL−1
amphotericin B. Afterwards a sterile 7.5 mgmL−1 stock of human ﬁbrinogen
(Sigma-Aldrich Company Ltd, Cat. No. F4883) in complete medium (without FBS)
was prepared at 37 °C in preparation for ﬁbrin formation. In order to label con-
ﬂuent hMSCs, cells were washed with 25 mL PBS and labelled with 25 mL (37 °C)
of 1 μM [sc_thrombin][ox890] in 60 mM HEPES (pH7) subsequently added prior
to incubation at 37 °C/5% CO2 for 20 min. Afterwards cells were immediately
washed with 25 mL PBS twice and trypsinised (8 mL) for 5 min in order to liberate
adherent hMSCs into a suspension, to which 16 mL of complete medium is added
(in order to inhibit further trypsin activity). The resulting suspension was then
centrifuged (400 × g, 25 °C, 5 min) with the supernatant discarded and replaced
with 25 mL of complete medium (without FBS) and centrifuged (400 × g, 25 °C, 5
min) once more with the supernatant discarded, this washing (i.e. FBS removal)
step was then repeated once more. The visible cell pellet was then resuspended in
complete medium (without FBS) to a total volume between 75–150 μL (dependant
on the number of constructs to be created). A 20 μL aliquot of resuspended hMSCs
(5 × 107 cells mL−1 was then added to 80 μL 7.5 mgmL−1 human ﬁbrinogen
preplaced into a precoated (agarose) well and gently mixed by pipetting. The
resulting mixture was then incubated at 37 °C/5% CO2 on an orbital rotator (50
rpm) for 60 min to promote and consolidate ﬁbrin gel formation (6 mgmL−1).
Afterwards cells were supplemented with 100 μL of the relevant medium (e.g.
adipogenic) containing 0.1 TIUmL−1 aprotinin with 3–5 media changes per week
for up to 23 days.
Scanning electron microscopy. Scanning electron microscopy (SEM) was per-
formed on a JSM IT300 Scanning Electron Microscope (Jeol Ltd., Japan). Fibrin
constructs were prepared as aforementioned and after 24 h ﬁxed in 4% (v/v)
Paraformaldehyde for 60 min. Samples were then dehydrated to 100% (v/v) ethanol
by 2 min immersions in 70, 80 and 90% (v/v) ethanol. Samples were then critically
point dried in a Leica EM CPD300 (Leica Microsystems Ltd., UK) mounted onto
SEM stubs and coated in gold using a high resolution Emitech K550X sputter
coater (Quorum Technologies Ltd., UK) prior to imaging.
Fibrin construct imaging. All live hMSC confocal microscopy was performed on a
Leica SP8 AOBS confocal laser scanning microscope attached to a Leica DM I6000
inverted epiﬂuorescence microscope (Leica Microsystems (UK) Ltd, UK) in a
temperature controlled (37 °C) environment. Prior to imaging, cells (labelled or
unlabelled) where indicated were stained with Calcein AM (1 μM) and Hoechst
33342 (5 μg μL−1) for a period of 20 min prior to imaging using the appropriate
excitation and emission wavelengths. Fibrinogen stocks were produced ad hoc
containing 0.1 mg of Alexa Fluor® 594 labelled human ﬁbrinogen (ThermoFisher
Scientiﬁc Ltd. Cat. No. F13193) per 0.9 mg of human ﬁbrinogen (unless otherwise
stated) freshly prepared in complete medium minus FBS which upon [sc_throm-
bin][ox890] mediated conversion to ﬁbrin allows for visualisation of the ﬁbrin
network using the appropriate excitation (594 nm) and emission (600+ nm)
wavelengths.
Quantitative reverse transcriptase PCR. Fibrin constructs (hMSCs derived from
three patients each with three biological replicates) were prepared as aforemen-
tioned and cultured with the appropriate differentiation media for a period of up to
14 days (as required) and isolated by trypsin digestion to yield a suspension of cells.
RNA extraction was performed using a RNeasy® Micro kit (Qiagen Ltd., UK. Cat.
No 74004) and followed the as supplied instructions. RNA concentration was then
determined using a P-330 nanophotometer (Implen GmbH, Germany) prior to
cDNA synthesis using an Omniscript® reverse transcriptase kit (Qiagen Ltd., UK.
Cat. No. 205111) following the as supplied instructions and 50 ng of template RNA.
Quantitative reverse transcriptase PCR (RT-qPCR) (with two technical duplicates)
was then performed on a StepOne Plus RT-qPCR instrument (Applied Biosystems
Inc., USA) with TaqMan® Universal Master Mix (II) (ThermoFisher Scientiﬁc Ltd.
Cat. No. 4440043) and corresponding TaqMan® gene expression assays for SOX9
(UniGene ID; Hs.647409), PPAR-γ (UniGene ID; Hs.162646), RUNX2 (UniGene
ID; Hs.535845) and (housekeeping) GAPDH (UniGene ID; Hs.544577). The raw Ct
values were collated and the ΔCt values determined and exponentiated to give the
relative expression levels reported.
Live cell mechanical testing. All mechanical testing was performed on a STAR-
RET FMS-500-L2 Force Measurement System (The L.S. Starrett Company Limited,
UK) ﬁtted with a 100 N load cells at room temperature. Constructs constituting a
volume of 400 μL ﬁbrin cast within a 48-well plate (Dia.= 11.0 mm; depth
∼4.2 mm;) were created using the same methodology as aforementioned, with all
components including cell number scaled up proportionally (i.e. 4-fold) with a ﬁnal
concentration of ﬁbrin of 6 mgmL−1. All samples were incubated at 37 °C/5% CO2
prior to analysis. Samples with hMSCs were supplemented with 400 μL of the
appropriate medium (i.e. complete, adipogenic, osteogenic) and aprotinin (0.1
TIU/mL). For the 23 day constructs, media was subsequently changed at frequent
(ﬁve times per week) intervals prior to analysis to permit differentiation and the
development of phenotypic characteristics. Constructs devoid of hMSCs were
catalysed by thrombin at a ﬁnal concentration of 200 nM. Prior to analysis, all
media was removed and the samples gently blotted to remove any residual liquid.
Samples were then cut using an 8 mm (Dia.) biopsy punch to create uniform ﬁbrin
discs. Each sample was then mounted onto a PLA stage and subjected to
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destructive compression testing at a rate of 1 mmmin−1. The compressive modulus
(kPa) of each sample was then calculated with the values reported representing the
mean (n= 4) ± standard error of the mean (s.e.m.).
Zebraﬁsh cell labelling. Wildtype and ET37 Zebraﬁsh (Danio rerio) were bred
and kept in accordance with approval from the local ethical review committee at
the University of Bristol and in accordance with UK Home Ofﬁce regulations. All
ﬁsh used were aged 4–18 months. ET37 ﬁsh express GFP under the control of an
unknown enhancer previously shown to label larval mesenchymal cells. To obtain
ﬁbroblasts for labelling and adoptive transfer, adult ET37 ﬁsh were anaesthetised in
0.13% MS-222 (Sigma-Aldrich Company Ltd, Cat. No. A5040) and the caudal ﬁn
resected. Pooled samples of ﬁns from four ﬁsh were collected into PBS containing
10 mM HEPES, 30 mM taurine and 5.5 mM glucose and cells dissociated by the
addition of 0.25% trypsin, 12.5 M CaCl2 and 5 mgml−1 Collagenase II (Wor-
thington Biochemical Corp.; Cat. No. LS004176). Dissociated cells were suspended
in Zebraﬁsh medium which comprised, Leibovitz medium (L-15) containing
0.3 mM glutamine, 0.8 mM CaCl2, 50 μg mL−1 Streptomycin, 50 UmL−1 Penicillin
and 2% (v/v) FBS. ET37+ ﬁbroblasts were sorted for GFP expression on a BD
Biosciences InFlux high-speed Fluorescence activated cell sorter (BD Biosciences
INC., San Jose, California). Sorted GFP+ cells were labelled with 1 μM
[sc_thrombin][ox890] as a suspension of 1 × 105 cells mL−1 for 20 min incubated
at 30 °C/5% CO2 in Zebraﬁsh medium plus 100 μg mL−1 Normocin (InvivoGen
Inc.; Cat. No. ant-nr-1) with FBS at 10% (v/v). Cells were then centrifuged (250 × g,
4 °C, 10 min) with the resulting supernatant discarded. Cells were then resus-
pended (1 × 106 cells mL−1) and washed once more by centrifugation before
resuspension at a ﬁnal concentration of 4 × 107 cells mL−1 prior to microinjection.
Zebraﬁsh adoptive cell transfer. Wildtype, non-ﬂuorescent recipient ﬁsh were
anaesthetised in 0.13% MS-222 and placed ventral side up in a pre-cut sponge
soaked in aquarium water containing anaesthetic. A 4-mm incision was made
through the skin and the pericardial sac directly above the heart. This area was
chosen as the underlying dermis is thicker than other sites and the procedure is
routinely preformed. Approximately 1000 GFP+ labelled or unlabelled cells in a
50 nL volume were microinjected at six sites around the edge of the incisional
injury and the ﬁsh allowed to recover in fresh system water without anaesthetic.
Zebraﬁsh imaging and staining procedures. At the desired time-points, recipient
ﬁsh were terminated and the area around the incision dissected and ﬁxed in 4% (v/
v) paraformaldehyde (PFA) for 1 h at room temperature, washed twice in PBS and
mounted in 1.5 wt.% low melting point agarose. Images of endogenous GFP
expression were acquired on a Leica DM6000 SP8 AOBS upright confocal laser
scanning microscope. For histological analysis, skin samples were decalciﬁed in 0.5
M EDTA (pH 7.4) at room temperature for 5 days, embedded in parafﬁn wax,
sectioned and stained as described previously53. Sections of 8 μm thickness were
stained with AFOG using standard protocols.
Data analysis. Data interpretation, modelling, numerical analysis and statistical
analysis were performed using Microsoft Excel for Mac 2011 (Microsoft Cor-
poration, WA, U.S.A), Prism 7 for Mac OS X (Graph Pad Inc., CA, U.S.A.) and
OriginPro 2015 (64-bit) Sr2 (OriginLab Corp., MA, USA). Statistical tests and
conﬁdence intervals detailing signiﬁcant differences are as described in the ﬁgure
legends of the appropriate ﬁgure.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the research ﬁndings in this study are available from the
corresponding author upon reasonable request. The source data underlying Figs. 2b, 3d,
5a, 5b, 5c, 6c and Supplementary Figs. 7a, 10 and 13 are provided as a Source Data ﬁle.
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